References
- Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, . Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550–7.
- Straathof KCM, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, . Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes. Blood. 2005;105:1898–904.
- Montagna D, Turin I, Schiavo R, Montini E, Zaffaroni N, Villa R, . Feasibility and safety of adoptive immunotherapy with ex-vivo generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy. 2011 Sep 23. [Epub ahead of print].
- Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nature Rev Immunol. 2009;9:353–63.
- Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, . Anti-tumor activity and long-term fate of chimeric antigen receptor positive T-cells in patients with neuroblastoma. Blood. 2011; Oct 7. [Epub ahead of print].
- Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–4.
- Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR, . Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood. 2007;110:2761–3.
- Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, . Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24:1160–70.
- Turin I, Pedrazzoli P, Tullio C, Montini E, La Grotteria MC, Schiavo R, . GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Cytotherapy. 2007;9:499–507.